PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 9:49 AM ET

Sponsor Check › Person

RA
No photo found yet (own website and image search run after this page is viewed)

Robert Adelman

Named as an officer, director or promoter on SEC Form D filings · CA, KY · Sep 9, 2009 → May 14, 2021

13deals (issuers)
$7.35Breported sold
957investors
31Form D filings
2009–2021years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:19 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Robert Adelman is listed as an executive officer and director on 31 SEC Form D filings by 13 issuers between Sep 2009 and May 2021. Largest by amount reported sold: Avoro Life Sciences Fund LLC (New York, NY — pooled investment fund — 2014–2016; $3.45B reported sold to 292 investors), Avoro Life Sciences Offshore Fund Ltd. (New York, NY — pooled investment fund — 2014–2016; $2.18B reported sold to 290 investors), venBio Global Strategic Fund IV, L.P. (San Francisco, CA — pooled investment fund — 2021; $549.9M reported sold to 147 investors), venBio Global Strategic Fund III, L.P. (San Francisco, CA — pooled investment fund — 2018–2020; $386.1M reported sold to 100 investors), venBio Global Strategic Fund II L.P. (San Francisco, CA — pooled investment fund — 2015–2017; $337M reported sold to 31 investors) and 8 more (all listed below).

What this means That is a lot of deals — 13 separate companies raised money with this person listed as executive officer and director, over about 12 years. Across those companies the filings report $7.35B sold in total.

Listed alongside Corey Goodman (22 shared filings), Paul Brooke (9 shared filings), Kurt von Emster (6 shared filings), venBio Select Advisor (6 shared filings, management entity), Richard Heyman (5 shared filings) and 65 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.

The issuers belong to 4 sponsor groups: Venbio (7 issuers, $1.97B reported sold, 2010–2024), Avoro (11 issuers, $10.15B reported sold, 2009–2026), Cerimon (3 issuers, $137.2M reported sold, 2009–2025) and Tp Therapeutics (2 issuers, $98M reported sold, 2014–2018).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 3 bankruptcy cases matching the name listed in Key records below.

What this means 3 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 31 public filings for Robert Adelman and found 16 differences, 4 worth asking the sponsor about: Amount sold went down between filings; Robert Adelman is no longer listed on the Oct 11, 2017 amendment; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Robert Adelman has not run yet — it is joining a line of 41,441 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:19 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Robert Adelman..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

3 cases: 3 closed (disposition not in docket feed)

ROBERT ADELMAN and EVE S ADELMAN closed
United States Bankruptcy Court, D. Arizona · No. 4:15-bk-10563 · Filed Aug 19, 2015 · Closed Dec 17, 2015
Role of ROBERT ADELMAN and EVE S ADELMAN: Debtor · Outcome: Case closed 2015-12-17 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); 3 people with this name in Form D filings; court in AR (not a filing state)
Robert D. Adelman closed
United States Bankruptcy Court, D. Massachusetts · No. 09-16602 · Filed Jul 14, 2009 · Closed Oct 19, 2009
Role of Robert D. Adelman: Debtor · Outcome: Case closed 2009-10-19 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); 3 people with this name in Form D filings; court in MA (not a filing state)
Robert Adelman closed
United States Bankruptcy Court, N.D. Illinois · No. 06-07762 · Filed Jun 30, 2006 · Closed May 17, 2010
Role of Robert Adelman: Debtor · Outcome: Case closed 2010-05-17 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); 3 people with this name in Form D filings; court in IL (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:19 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

16 differences found between the filings for Robert Adelman — 4 worth asking about (compared 31 filings on Oct 24, 2026)

Note · Nov 30, 2010 – Feb 2, 2012

Bankruptcy case: Heritage Pacific Financial LLC v. Countouriotis — filed Nov 30, 2010

United States Bankruptcy Court, E.D. California docket "Heritage Pacific Financial LLC v. Countouriotis" filed Nov 30, 2010, closed Feb 2, 2012. Athena Countouriotis (listed on the same filings) is listed as Defendant ("Countouriotis"). Our match estimate: 70%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, E.D. California ↗Athena Countouriotis — PartnerFacts page ↗
Sources
Worth asking · Sep 9, 2009 – Apr 2, 2010

Amount sold went down between filings — Cerimon Pharmaceuticals, Inc.

The Sep 9, 2009 filing says $1,500,003 sold; the Apr 2, 2010 Form D says $750,000 sold — $750,003 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Form D (earlier) · Sep 9, 2009 ↗Form D (later) · Apr 2, 2010 ↗Cerimon Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Dec 28, 2012

Robert Adelman appears on 1 deal that stopped filing before reaching its target

Labrys Biologics, Inc. (last filing Dec 28, 2012; $14,588,234 sold of $30,999,997). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Labrys Biologics, Inc. — PartnerFacts page ↗
Sources
Note · Dec 24, 2015 – Feb 8, 2016

Form D filed 46 days after the first sale — Apellis Pharmaceuticals, Inc.

The filing says the first sale was Dec 24, 2015. The Form D was filed Feb 8, 2016 — 46 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 31 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Form D · Feb 8, 2016 ↗Apellis Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Nov 3, 2010 – May 14, 2021

4 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — venBio Global Strategic Fund IV, L.P. (latest filing May 14, 2021) · No amendment in the last 12 months on an offering that may still be open — Apellis Pharmaceuticals, Inc. (latest filing Aug 17, 2017) · No amendment in the last 12 months on an offering that may still be open — venBio Global Strategic Fund, L.P. (latest filing Oct 29, 2013) · No amendment in the last 12 months on an offering that may still be open — Labrys Biologics, Inc. (latest filing Dec 28, 2012)

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · May 14, 2021 ↗venBio Global Strategic Fund IV, L.P. — PartnerFacts page ↗Form D · Aug 17, 2017 ↗Apellis Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Worth asking · Oct 11, 2016 – Oct 11, 2017

Robert Adelman is no longer listed on the Oct 11, 2017 amendment — Avoro Life Sciences Offshore Fund Ltd.

Robert Adelman appears on the Oct 11, 2016 Form D/A (executive officer) but not on the Oct 11, 2017 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D/A · Oct 11, 2016 ↗Form D/A · Oct 11, 2017 ↗Robert Adelman — PartnerFacts page ↗Avoro Life Sciences Offshore Fund Ltd. — PartnerFacts page ↗
Sources
Worth asking · Oct 11, 2016 – Oct 11, 2017

Robert Adelman is no longer listed on the Oct 11, 2017 amendment — Avoro Life Sciences Fund LLC

Robert Adelman appears on the Oct 11, 2016 Form D/A (executive officer) but not on the Oct 11, 2017 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D/A · Oct 11, 2016 ↗Form D/A · Oct 11, 2017 ↗Robert Adelman — PartnerFacts page ↗Avoro Life Sciences Fund LLC — PartnerFacts page ↗
Sources
Worth asking · Sep 9, 2009 – Jun 24, 2010

Robert Adelman is no longer listed on the Jun 24, 2010 amendment — Cerimon Pharmaceuticals, Inc.

Robert Adelman appears on the Sep 9, 2009 Form D (director) but not on the Jun 24, 2010 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Sep 9, 2009 ↗Form D/A · Jun 24, 2010 ↗Robert Adelman — PartnerFacts page ↗Cerimon Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Sep 9, 2009 – Mar 26, 2020

8 offerings changed their target amount between filings

Offering amount changed between filings — venBio Global Strategic Fund III, L.P. · Offering amount changed between filings — venBio Global Strategic Fund II L.P. · Offering amount changed between filings — Metacrine, Inc. · Offering amount changed between filings — venBio Global Strategic Fund II L.P. · Offering amount changed between filings — Metacrine, Inc. · and 3 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D/A (earlier) · Mar 26, 2019 ↗Form D/A (later) · Mar 26, 2020 ↗venBio Global Strategic Fund III, L.P. — PartnerFacts page ↗Form D/A (earlier) · Mar 18, 2016 ↗
Sources
Note · Mar 26, 2019 – Mar 26, 2020

Minimum investment changed between filings — venBio Global Strategic Fund III, L.P.

The Mar 26, 2019 filing lists a minimum of $5,000,000; the Mar 26, 2020 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D/A (earlier) · Mar 26, 2019 ↗Form D/A (later) · Mar 26, 2020 ↗venBio Global Strategic Fund III, L.P. — PartnerFacts page ↗
Sources
Note · Jun 13, 2018 – Mar 26, 2019

Minimum investment changed between filings — venBio Global Strategic Fund III, L.P.

The Jun 13, 2018 filing lists a minimum of $0; the Mar 26, 2019 Form D/A lists $5,000,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Jun 13, 2018 ↗Form D/A (later) · Mar 26, 2019 ↗venBio Global Strategic Fund III, L.P. — PartnerFacts page ↗
Sources
Note · May 12, 2015 – Mar 15, 2019

Same name, different state: "Robert Adelman" (NC) is a separate record

This page covers filings where the address state is CA or KY. A separate record, "Robert Adelman" with address state NC, is listed on 3 filings — most recently by PRECISION BIOSCIENCES INC (Mar 15, 2019). Both records have filings in the same period (May 12, 2015 to Mar 15, 2019).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Robert Adelman (NC) — PartnerFacts page ↗Form D · Mar 15, 2019 ↗PRECISION BIOSCIENCES INC — PartnerFacts page ↗Robert Adelman (CA,KY) — this page ↗
Sources
Note · Jun 6, 2012

Same name, different state: "Robert Adelman" (NY) is a separate record

This page covers filings where the address state is CA or KY. A separate record, "Robert Adelman" with address state NY, is listed on 1 filing — most recently by Sientra, Inc. (Jun 6, 2012). Both records have filings in the same period (Jun 6, 2012).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Robert Adelman (NY) — PartnerFacts page ↗Form D · Jun 6, 2012 ↗Sientra, Inc. — PartnerFacts page ↗Robert Adelman (CA,KY) — this page ↗
Sources
Note · Oct 11, 2016 – Oct 11, 2017

Address moved from San Francisco, CA to New York, NY — Avoro Life Sciences Offshore Fund Ltd.

The people listed on the Oct 11, 2016 filing give San Francisco, CA; on the Oct 11, 2017 filing they give New York, NY. The address now on file (110 Greene Street, Suite 800, New York, NY) is a registered-agent or shared-office address used by 28 issuers.

What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.

Form D/A · Oct 11, 2016 ↗Form D/A · Oct 11, 2017 ↗Avoro Life Sciences Offshore Fund Ltd. — PartnerFacts page ↗
Sources
Note · Oct 11, 2016 – Oct 11, 2017

Address moved from San Francisco, CA to New York, NY — Avoro Life Sciences Fund LLC

The people listed on the Oct 11, 2016 filing give San Francisco, CA; on the Oct 11, 2017 filing they give New York, NY. The address now on file (110 Greene Street, Suite 800, New York, NY) is a registered-agent or shared-office address used by 28 issuers.

What this means A registered agent's address is a mailbox, not where the team works. Ask where the business actually operates.

Form D/A · Oct 11, 2016 ↗Form D/A · Oct 11, 2017 ↗Avoro Life Sciences Fund LLC — PartnerFacts page ↗
Sources
Note · Sep 9, 2009 – May 14, 2021

Robert Adelman is listed with 2 different address states: CA, KY

CA on 30 filings (Sep 9, 2009 to May 14, 2021); KY on 1 filing (Aug 17, 2017).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Sep 9, 2009 ↗Form D · Aug 17, 2017 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

3 of 19 offerings report sales commissions totalling $7,345,238; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
May 14, 2021 D
venBio Global Strategic Fund IV, L.P.
File 021-399537
$2,435,860 (est.)$0$0BA Securities LLC BrokerCheck CRD 153489 ↗
Far Hills Group, LLC BrokerCheck CRD 32243 ↗		EDGAR ↗
Mar 26, 2020 D/A
venBio Global Strategic Fund III, L.P.
File 021-314554
$0 (est.)$0 (est.)$0 (est.)
An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement.
Far Hills Group LLC BrokerCheck CRD 32243 ↗
BA Securities, LLC BrokerCheck CRD 153489 ↗		EDGAR ↗
Oct 30, 2018 D
TP Therapeutics, Inc.
File 021-324635
$0$0$0None listed on this filingEDGAR ↗
Jun 20, 2018 D
Metacrine, Inc.
File 021-314940
$0$0$0None listed on this filingEDGAR ↗
Dec 13, 2017 D
Metacrine, Inc.
File 021-300578
$0$0$0None listed on this filingEDGAR ↗
Aug 17, 2017 D
Apellis Pharmaceuticals, Inc.
File 021-293019
$0$0$0None listed on this filingEDGAR ↗
Mar 2, 2017 D/A
venBio Global Strategic Fund II L.P.
File 021-236281
$0$0$0 (est.)
An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Nov 9, 2016 D/A
Metacrine, Inc.
File 021-237785
$0$0$0None listed on this filingEDGAR ↗
Oct 11, 2016 D/A
Avoro Life Sciences Offshore Fund Ltd.
File 021-146407
$3,138,096 (est.)$0 (est.)$0 (est.)
Issuer's investment manager and its principals receive a management fee based on the value of the issuer's assets and/or a performance allocation based on the issuer's profits, calculated per the offering documents; includes proceeds from a master fund.
Far Hills Group LLC BrokerCheck CRD 32243 ↗
Direct Access Partners, LLC BrokerCheck CRD 120950 ↗		EDGAR ↗
Oct 11, 2016 D/A
Avoro Life Sciences Fund LLC
File 021-146405
$1,771,282 (est.)$0 (est.)$0 (est.)
Issuer's managing member and its principals receive a management fee based on the value of the issuer's assets and/or a performance allocation based on the issuer's profits, calculated per the offering documents; includes proceeds from a feeder fund.
Far Hills Group LLC BrokerCheck CRD 32243 ↗EDGAR ↗
Feb 8, 2016 D
Apellis Pharmaceuticals, Inc.
File 021-256958
$0$0$0None listed on this filingEDGAR ↗
Dec 30, 2015 D
Solstice Biologics LLC
File 021-254171
$0$0$0None listed on this filingEDGAR ↗
Oct 3, 2014 D
Solstice Biologics LLC
File 021-225788
$0$0$0None listed on this filingEDGAR ↗
Oct 29, 2013 D/A
venBio Global Strategic Fund, L.P.
File 021-150376
$0$0$0 (est.)
An affiliate of the general partner (or its designee) will receive an annual fee for management services equal to a percentage of each investor's subscription to the Issuer, as specified in the Issuer's partnership agreement.
None listed on this filingEDGAR ↗
Dec 28, 2012 D
Labrys Biologics, Inc.
File 021-189143
$0$0$0None listed on this filingEDGAR ↗
Dec 28, 2012 D
Solstice Biologics LLC
File 021-189144
$0$0$0None listed on this filingEDGAR ↗
Dec 12, 2012 D
Solstice Biologics LLC
File 021-188236
$0$0$0None listed on this filingEDGAR ↗
Sep 25, 2012 D
Aragon Pharmaceuticals, Inc.
File 021-184610
$0$0$0None listed on this filingEDGAR ↗
Sep 9, 2009 D
Cerimon Pharmaceuticals, Inc.
File 021-77816
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 13

Every issuer that named Robert Adelman on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

VG
Pooled Investment Fund · group: Venbio

venBio Global Strategic Fund IV, L.P.

San Francisco, CA · May 14, 2021
  • May 14, 2021 · D · $549,936,000 sold of $550,000,000 · 147 investors · min. $125,000 · role: Executive Officer EDGAR ↗

Raised $549.9M from 147 investors (100% of the $550M target) as of the latest filing. Robert is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VG
Pooled Investment Fund · group: Venbio

venBio Global Strategic Fund III, L.P.

San Francisco, CA · Jun 13, 2018 → Mar 26, 2020 · 3 filings
  • Mar 26, 2020 · D/A · $386,055,000 sold of $386,055,000 · 100 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗
  • Mar 26, 2019 · D/A · $118,000,000 sold of $350,000,000 · 8 investors · min. $5,000,000 · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗
  • Jun 13, 2018 · D · $0 sold of $350,000,000 · 0 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗

Raised $386.1M from 100 investors (100% of the $386.1M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TT
Pharmaceuticals · group: Tp Therapeutics

TP Therapeutics, Inc.

San Diego, CA · Oct 30, 2018
  • Oct 30, 2018 · D · $80,000,016 sold of $80,000,016 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $80M from 16 investors (100% of the $80M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

M
Pharmaceuticals

Metacrine, Inc.

San Diego, CA · Oct 6, 2015 → Jun 20, 2018 · 4 filings
  • Jun 20, 2018 · D · $65,000,000 sold of $65,000,000 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 13, 2017 · D · $22,000,000 sold of $22,000,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 9, 2016 · D/A · $37,766,644 sold of $37,766,644 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 6, 2015 · D/A · $12,149,995 sold of $36,449,979 · 18 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $65M from 26 investors (100% of the $65M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Pharmaceuticals · group: Apellis

Apellis Pharmaceuticals, Inc.

Crestwood, KY · Feb 8, 2016 → Aug 17, 2017 · 2 filings
  • Aug 17, 2017 · D · $20,033,322 sold of $60,099,974 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 8, 2016 · D · $47,135,951 sold of $47,135,951 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $47.1M from 25 investors (78% of the $60.1M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VG
Pooled Investment Fund · group: Venbio

venBio Global Strategic Fund II L.P.

San Francisco, CA · Mar 19, 2015 → Mar 2, 2017 · 3 filings
  • Mar 2, 2017 · D/A · $337,000,000 sold of $337,000,000 · 31 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗
  • Mar 18, 2016 · D/A · $288,000,000 sold of $303,000,000 · 22 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗
  • Mar 19, 2015 · D · $0 sold of $250,000,000 · 0 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗

Raised $337M from 31 investors (100% of the $337M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AL
Pooled Investment Fund · group: Avoro

Avoro Life Sciences Offshore Fund Ltd.

New York, NY · Oct 17, 2014 → Oct 11, 2016 · 3 filings
  • Oct 11, 2016 · D/A · $249,289,000 sold of Indefinite · 96 investors · min. $1,000,000 · role: Executive Officer (Managing member of venBio Select Advisor LLC.) EDGAR ↗
  • Oct 9, 2015 · D/A · $178,486,500 sold of Indefinite · 82 investors · min. $1,000,000 · role: Executive Officer (Managing member of venBio Select Advisor LLC.) EDGAR ↗
  • Oct 17, 2014 · D/A · $65,840,000 sold of Indefinite · 51 investors · min. $1,000,000 · role: Executive Officer (Managing member of venBio Select Advisor LLC.) EDGAR ↗

Raised $2.18B from 290 investors as of the latest filing. Robert is listed as executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AL
Pooled Investment Fund · group: Avoro

Avoro Life Sciences Fund LLC

New York, NY · Oct 17, 2014 → Oct 11, 2016 · 3 filings
  • Oct 11, 2016 · D/A · $412,916,742 sold of Indefinite · 108 investors · min. $1,000,000 · role: Executive Officer (Managing member of venBio Select Advisor LLC.) EDGAR ↗
  • Oct 9, 2015 · D/A · $292,582,529 sold of Indefinite · 96 investors · min. $1,000,000 · role: Executive Officer (Managing member of venBio Select Advisor LLC.) EDGAR ↗
  • Oct 17, 2014 · D/A · $123,974,500 sold of Indefinite · 42 investors · min. $1,000,000 · role: Executive Officer (Managing member of venBio Select Advisor LLC.) EDGAR ↗

Raised $3.45B from 292 investors as of the latest filing. Robert is listed as executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Pharmaceuticals · group: Venbio

Solstice Biologics LLC

San Francisco, CA · Dec 12, 2012 → Dec 30, 2015 · 4 filings
  • Dec 30, 2015 · D · $4,000,000 sold of $4,000,000 · 2 investors · min. No minimum reported · role: Director (Mr. Adelman is a member of the Board of Managers of the Issuer.) EDGAR ↗
  • Oct 3, 2014 · D · $7,500,000 sold of $7,500,000 · 2 investors · min. No minimum reported · role: Director (Mr. Adelman is a Manager of the Issuer.) EDGAR ↗
  • Dec 28, 2012 · D · $7,500,000 sold of $7,500,000 · 2 investors · min. No minimum reported · role: Director (Mr. Adelman is a Manager of the Issuer.) EDGAR ↗
  • Dec 12, 2012 · D · $3,000,000 sold of $3,000,000 · 1 investors · min. No minimum reported · role: Director (Mr. Adelman is a Manager of the Issuer.) EDGAR ↗

Raised $7.5M from 2 investors (100% of the $4M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VG
Pooled Investment Fund · group: Venbio

venBio Global Strategic Fund, L.P.

San Francisco, CA · Nov 12, 2010 → Oct 29, 2013 · 4 filings
  • Oct 29, 2013 · D/A · $177,000,000 sold of $237,000,000 · 4 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗
  • Oct 31, 2012 · D/A · $177,000,000 sold of $177,500,000 · 4 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗
  • Nov 3, 2011 · D/A · $175,000,000 sold of $177,500,000 · 3 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗
  • Nov 12, 2010 · D · $75,000,000 sold of $175,000,000 · 1 investors · min. No minimum reported · role: Director (Director of the General Partner of the Issuer's General Partner) EDGAR ↗

Raised $177M from 4 investors (75% of the $237M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LB
Pharmaceuticals · group: Venbio

Labrys Biologics, Inc.

San Francisco, CA · Dec 28, 2012
  • Dec 28, 2012 · D · $14,588,234 sold of $30,999,997 · 5 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

Raised $14.6M from 5 investors (47% of the $31M target) as of the latest filing. Robert is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AP
Pharmaceuticals

Aragon Pharmaceuticals, Inc.

San Diego, CA · Sep 25, 2012
  • Sep 25, 2012 · D · $49,999,988 sold of $49,999,988 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $50M from 9 investors (100% of the $50M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

CP
Pharmaceuticals · group: Cerimon

Cerimon Pharmaceuticals, Inc.

South San Francisco, CA · Sep 9, 2009
  • Sep 9, 2009 · D · $1,500,003 sold of $1,500,003 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $1.5M from 10 investors (100% of the $1.5M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (2)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Robert Adelman — NY, 1 issuer, Jun 6, 2012 → Jun 6, 2012 · no shared issuer
  • Robert Adelman — NC, 1 issuer, May 12, 2015 → Mar 15, 2019 · no shared issuer

People around Robert 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

VS
Management entity

venBio Select Advisor

Promoter · 6 shared filings (2 issuers)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

VG
Management entity

venBio Global Strategic GP, Ltd.

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

VM
Management entity

venBio Management Company LLC

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Corey Goodman

Director, Executive Officer, Promoter · 22 shared filings (8 issuers) · also on 13 other issuers

Corey Goodman is on 21 issuers in total — a repeat sponsor. Their page lists every one.

PB
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Brooke

Director, Executive Officer · 9 shared filings (4 issuers)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

KE
No photo found yet (own website and image search run after this page is viewed)
Person

Kurt von Emster

Director, Executive Officer · 6 shared filings (3 issuers) · also on 10 other issuers

Kurt von Emster is on 13 issuers in total — a repeat sponsor. Their page lists every one.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Heyman

Executive Officer, Director · 5 shared filings (2 issuers) · also on 6 other issuers

Richard Heyman is on 8 issuers in total — a repeat sponsor. Their page lists every one.

AN
No photo found yet (own website and image search run after this page is viewed)
Person

Amir Nashat

Director · 4 shared filings (1 issuer) · also on 28 other issuers

Amir Nashat is on 29 issuers in total — a repeat sponsor. Their page lists every one.

KB
No photo found yet (own website and image search run after this page is viewed)
Person

Kristina Burow

Director · 4 shared filings (1 issuer) · also on 31 other issuers

Kristina Burow is on 32 issuers in total — a repeat sponsor. Their page lists every one.

SD
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Dowdy

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

CB
No photo found yet (own website and image search run after this page is viewed)
Person

Curt Bradshaw

Director, Executive Officer, Promoter · 4 shared filings (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

RE
No photo found yet (own website and image search run after this page is viewed)
Person

Ronald Evans

Director · 4 shared filings (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

AR
No photo found yet (own website and image search run after this page is viewed)
Person

Aaron Royston

Executive Officer · 4 shared filings (2 issuers) · also on 7 other issuers

Aaron Royston is on 9 issuers in total — a repeat sponsor. Their page lists every one.

SE
No photo found yet (own website and image search run after this page is viewed)
Person

Scott Epstein

Executive Officer · 4 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Robert Adelman. Their page shows their other deals.

BA
No photo found yet (own website and image search run after this page is viewed)
Person

Behzad Aghazadeh

Executive Officer · 4 shared filings (2 issuers) · also on 4 other issuers

Behzad Aghazadeh is on 6 issuers in total — a repeat sponsor. Their page lists every one.

DP
No photo found yet (own website and image search run after this page is viewed)
Person

David Pezeshki

Executive Officer · 4 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Robert Adelman. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carol Gallagher

Director · 3 shared filings (2 issuers) · also on 13 other issuers

Carol Gallagher is on 15 issuers in total — a repeat sponsor. Their page lists every one.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carl L. Gordon

Director · 2 shared filings (2 issuers) · also on 60 other issuers

Carl L. Gordon is on 62 issuers in total — a repeat sponsor. Their page lists every one.

BC
No photo found yet (own website and image search run after this page is viewed)
Person

Bihua Chen

Director · 2 shared filings (1 issuer) · also on 29 other issuers

Bihua Chen is on 30 issuers in total — a repeat sponsor. Their page lists every one.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Patricia Millican

Executive Officer · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Adelman. Their page shows their other deals.

SD
No photo found yet (own website and image search run after this page is viewed)
Person

Sinclair Dunlop

Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Adelman. Their page shows their other deals.

GC
No photo found yet (own website and image search run after this page is viewed)
Person

Gerald Chan

Director · 2 shared filings (1 issuer) · also on 10 other issuers

Gerald Chan is on 11 issuers in total — a repeat sponsor. Their page lists every one.

SB
No photo found yet (own website and image search run after this page is viewed)
Person

Stephanie O'Brien

Director · 2 shared filings (1 issuer) · also on 7 other issuers

Stephanie O'Brien is on 8 issuers in total — a repeat sponsor. Their page lists every one.

CF
No photo found yet (own website and image search run after this page is viewed)
Person

Cedric Francois

Executive Officer, Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Robert Adelman. Their page shows their other deals.

PD
No photo found yet (own website and image search run after this page is viewed)
Person

Pascal Deschatelets

Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Adelman. Their page shows their other deals.

BZ
No photo found yet (own website and image search run after this page is viewed)
Person

Brett Zbar

Director · 2 shared filings (2 issuers)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

AM
No photo found yet (own website and image search run after this page is viewed)
Person

Alec Machiels

Director · 2 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Robert Adelman. Their page shows their other deals.

FM
No photo found yet (own website and image search run after this page is viewed)
Person

Frank Muhlenbeck

Director · 2 shared filings (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

JB
No photo found yet (own website and image search run after this page is viewed)
Person

John Borgeson

Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Adelman. Their page shows their other deals.

DW
No photo found yet (own website and image search run after this page is viewed)
Person

David Watson

Executive Officer · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Adelman. Their page shows their other deals.

TM
No photo found yet (own website and image search run after this page is viewed)
Person

Trisha Millican

Executive Officer · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Adelman. Their page shows their other deals.

DG
No photo found yet (own website and image search run after this page is viewed)
Person

Daniel Geffken

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

NP
No photo found yet (own website and image search run after this page is viewed)
Person

Nicole Perry

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Robert Adelman. Their page shows their other deals.

KS
No photo found yet (own website and image search run after this page is viewed)
Person

Ken Song

Executive Officer, Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Adelman. Their page shows their other deals.

RG
No photo found yet (own website and image search run after this page is viewed)
Person

Richard Gaster

Executive Officer · 1 shared filing (1 issuer) · also on 5 other issuers

Richard Gaster is on 6 issuers in total — a repeat sponsor. Their page lists every one.

PS
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Svennilson

Director · 1 shared filing (1 issuer) · also on 20 other issuers

Peter Svennilson is on 21 issuers in total — a repeat sponsor. Their page lists every one.

YL
No photo found yet (own website and image search run after this page is viewed)
Person

Yishan Li

Director · 1 shared filing (1 issuer) · also on 3 other issuers

Listed on the same filings as Robert Adelman. Their page shows their other deals.

The team behind the deals

V
Sponsor group

Venbio

7 issuers · 17 filings · $1.97B reported sold · 2010–2024

One team, 7 deal companies. Robert Adelman is listed on 6 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Adelman.

A
Sponsor group

Avoro

11 issuers · 112 filings · $10.15B reported sold · 2009–2026

One team, 11 deal companies. Robert Adelman is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Adelman.

C
Sponsor group

Cerimon

3 issuers · 9 filings · $137.2M reported sold · 2009–2025

One team, 3 deal companies. Robert Adelman is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Adelman.

TT
Sponsor group

Tp Therapeutics

2 issuers · 4 filings · $98M reported sold · 2014–2018

One team, 2 deal companies. Robert Adelman is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Adelman.

A
Sponsor group

Apellis

3 issuers · 20 filings · $24.9M reported sold · 2010–2025

One team, 3 deal companies. Robert Adelman is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Adelman.

Same business address

42 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

A person is never an adviser firm. 2 of the 13 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): Avoro Life Sciences Offshore Fund Ltd., Avoro Life Sciences Fund LLC.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Robert Adelman by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 13 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Robert Adelman is listed on: none on file. No website or social profile named in venBio Global Strategic Fund IV, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #191,293 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (San Francisco, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗Kentucky state courts — find the court ↗New York WebCivil Supreme ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗Kentucky Secretary of State business search ↗New York Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Robert Adelman appears on a new Form D, or when a court case or SEC action is matched to them. See plans →